Jiwon Oh, Paul W. O'Connor

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration. Furthermore, existing clinical experience with its parent drug, leflunomide, provides indirect long-term safety data. This review summarizes teriflunomide's pharmacologic properties, pivotal clinical trials, and safety profile, and ends with a discussion of the role of teriflunomide in the context of current and emerging MS treatment options.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalNeurology: Clinical Practice
Issue number3
StatePublished - Jun 2013

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Teriflunomide'. Together they form a unique fingerprint.

Cite this